Cardiovascular morbidity and mortality associated with the metabolic syndrome.

By B. Isomaa, P. Almgren, T. Tuomi, B. Forsén, K. Lahti, M. Nissen, Marja-Riitta Taskinen, Leif Groop. Diabetes Care, 2001

4,989 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/0327b5182f17b618b44dc25cdeb141567909ad35

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. E. Ford
2. P. Ridker
3. P. Zimmet
4. Ralph DeFronzo
5. R. Eckel
6. J. Shaw
7. S. Grundy
8. Marja-Riitta Taskinen

In Epidemiology

1. P. Ridker
2. Ralph DeFronzo
3. E. Ford
4. R. Eckel
5. Christian K. Roberts
6. R. J. Barnard
7. N. Rifai
8. P. Zimmet

In Molecular Biology

1. E. Ford
2. Ralph DeFronzo
3. George P. Chrousos
4. Bart Staels
5. Gregory E. Miller
6. Ronald C. Petersen
7. Stephen B. Kritchevsky
8. N. Rifai

Citations in the corpus

• Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. (2005, methodology): “Among studies of cardiovascular disease, two (20,25) used the most exact WHO definition.”
• Therapeutic roles of peroxisome proliferator-activated receptor agonists. (2005, background): “A substudy of the Botnia trial demonstrated that the effect of clustering of metabolic syndrome components on the risk of CHD morbidity in individuals with the metabolic syndrome appears greater than the relative risk associated with the individual components (58).”
• Global and societal implications of the diabetes epidemic (2001, background): “The reliability of this definition in terms of predicting the prevalence of, and the CVD risk associated with, the metabolic syndrome has been reported recentl”
• Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? (2004, background): “This becomes especially pertinent given that Asia is the region in which the prevalence diabetes and CVD are likely to see the largest in - creases in the near future .”
• Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training (2013, neutral): “Landin et al. (380) suggested that elevated serum levels of fibrinogen and tissue plasminogen activator inhibitor were related to metabolic factors for CHD. Small dense particles of low-density lipoprotein (LDL) were found to have increased atherogenicity compared to large, less dense particles (604”
• Metabolic syndrome: definitions and controversies (2011, background): “Several epidemiological studies have confirmed the increased risk of CVD in individuals with MetS, independently of the diagnostic criteria used [32-39].”